Physician profile
Roxanne Boyd
NPI 1801281191
$4,105.59
in general payments reported to CMS, 2019-2025
32 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $79.19 · 2021: $310 · 2022: $461 · 2023: $996 · 2024: $1,079 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,993 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.15 |
| Education | $142.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $727.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $339.02 | 2023-2025 | Veozah |
| Lilly USA, LLC | $292.47 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $287.61 | 2021-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $267.73 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $234.94 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $190.97 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.28 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $145.21 | 2024-2025 | Rexulti |
| Abbott Laboratories | $125.16 | 2022-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $110.55 | 2019-2025 | Fanapt |
| Mylan Specialty L.P. | $109.60 | 2022-2024 | Yupelri |
| Vifor Pharma, INC. | $106.81 | 2019 | |
| Xeris Pharmaceuticals, INC. | $105.50 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Verona Pharma, INC. | $100.97 | 2025 | Ohtuvayre |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $100.44 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $94.68 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Evofem Biosciences, INC. | $86.50 | 2022-2024 | Phexxi |
| Exact Sciences Corporation | $82.29 | 2023-2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $73.63 | 2025 | Yupelri |
| Amgen INC. | $57.76 | 2023 | Repatha, Otezla |
| Myriad Women'S Health, INC. | $48.29 | 2023 | Myrisk |
| Mannkind Corporation | $42.50 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.90 | 2022 | |
| Gilead Sciences, INC. | $32.24 | 2023 | Epclusa |
| Cequr Corporation | $25.90 | 2024 | Cequr Simplicity |
| Dexcom, INC. | $24.26 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $22.63 | 2025 | Omnipod |
| Alkermes, INC. | $18.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.18 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $13.91 | 2021 | |
| Dynavax Technologies Corporation | $13.07 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.